Rain Oncology Inc. financial data

Location
8000 Jarvis Avenue, Suite 204, Newark, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Rain Therapeutics Inc. (to 12/29/2022)
Latest financial report
10-Q - Q3 2023 - Nov 9, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 563 % -35.5%
Debt-to-equity 21.5 % +64%
Return On Equity -83 % -24%
Return On Assets -68.3 % -15.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.4M shares +36.9%
Common Stock, Shares, Outstanding 36.4M shares +36.9%
Entity Public Float 43.9M USD -63.4%
Common Stock, Value, Issued 37K USD +37%
Weighted Average Number of Shares Outstanding, Basic 36.4M shares +36.9%
Weighted Average Number of Shares Outstanding, Diluted 36.4M shares +36.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 54.7M USD -4.03%
General and Administrative Expense 19.1M USD +30.1%
Operating Income (Loss) -76.6M USD -6.91%
Nonoperating Income (Expense) 4.35M USD +594%
Net Income (Loss) Attributable to Parent -72.3M USD -1.73%
Earnings Per Share, Basic -2.07 USD/shares +72.1%
Earnings Per Share, Diluted -2.07 USD/shares +72.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 37.3M USD -6.33%
Other Assets, Current 281K USD +243%
Assets, Current 80.8M USD -13.8%
Property, Plant and Equipment, Net 628K USD +510%
Operating Lease, Right-of-Use Asset 436K USD +49.8%
Other Assets, Noncurrent 180K USD -63.7%
Assets 82.1M USD -13.3%
Accounts Payable, Current 8.97M USD +120%
Liabilities, Current 14.5M USD +11.3%
Operating Lease, Liability, Noncurrent 39K USD -78.9%
Other Liabilities, Noncurrent 64K USD 0%
Liabilities 14.5M USD +9.94%
Accumulated Other Comprehensive Income (Loss), Net of Tax -64K USD +78.8%
Retained Earnings (Accumulated Deficit) -215M USD -50.5%
Stockholders' Equity Attributable to Parent 67.5M USD -17.1%
Liabilities and Equity 82.1M USD -13.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21.8M USD -27.6%
Net Cash Provided by (Used in) Financing Activities 466K USD +16.8%
Net Cash Provided by (Used in) Investing Activities 3.52M USD -73.8%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 36.4M shares +36.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.9M USD -445%
Deferred Tax Assets, Valuation Allowance 54.1M USD +139%
Deferred Tax Assets, Gross 54.2M USD +138%
Operating Lease, Liability 456K USD +46.2%
Depreciation 22M USD +46.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -72M USD -0.96%
Lessee, Operating Lease, Liability, to be Paid 477K USD +39.5%
Property, Plant and Equipment, Gross 1.05M USD +228%
Operating Lease, Liability, Current 456K USD +180%
Lessee, Operating Lease, Liability, to be Paid, Year Two 129K USD -24.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 358K USD +109%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 21K USD -30%
Deferred Tax Assets, Operating Loss Carryforwards 29.2M USD +71.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 4.02M USD +179%
Operating Lease, Payments 237K USD +43.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 75K USD -7.41%
Share-based Payment Arrangement, Expense 4.9M USD +0.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares